5 billion people have access to medicine 2 billion to go


The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

New online: the first Antimicrobial Resistance Benchmark

First independent assessment of pharma company action on AMR

The 2018 Antimicrobial Resistance Benchmark is now online. It is the first report to assess how pharmaceutical companies are tackling rising rates of drug-resistant infections. The Benchmark finds evidence of good practice in multiple areas – the task now is to expand them to more products.
Watch the live launch at the WEF >>

Foundation to co-host events at WHO World Health Assembly

18 May 2018
The Foundation will co-host two during the WHO’s 71st annual World Health Assembly (WHA). On Tuesday 22 May, speakers will explore game changers in global health; on Wednesday 23 May, the focus is on the big questions surrounding access to quality medicines. Jayasree K. Iyer, Foundation Executive Director, will speak at both events.

Work starts on metrics for the 2020 AMR Benchmark

19 Apr 2018
The Access to Medicine Foundation has started the methodology review for the next Antimicrobial Resistance Benchmark. The Foundation is consulting a wide range of experts and stakeholders to explore how to refine its analysis of pharmaceutical company responses to antimicrobial resistance.

Access to Medicine Foundation in India to discuss AMR strategies

12 Mar 2018
India is home to more than a billion people, who face increasing rates of drug resistance. From 12-16 March, the Access to Medicine Foundation will be in New Delhi and Mumbai, India, to meet with Indian-based pharmaceutical companies and government representatives to share ideas and opportunities to limit drug resistance. The Foundation’s Executive Director, Jayasree K. Iyer, will also speak at the Delhi End TB Summit.

New IP-sharing framework to accelerate R&D

21 Feb 2018
The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs).

The first Benchmark launches at the WEF in Davos

24 Jan 2018
At 14:00 CET on Tuesday 23 January, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, will launch the first Antimicrobial Resistance Benchmark in a livestreamed WEF press conference.

Live WEF discussion with Bill Gates & Jayasree Iyer at 1pm CET: “New Era For Global Health”

25 Jan 2018
Jayasree K. Iyer joins Bill Gates and others to discuss how new leadership, policy and business models are rewriting the global health playbook.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

Antimicrobial Resistance Benchmark 2018

The first detailed analysis of pharmaceutical company action against antimicrobial resistance.

Visit website

We’re hiring!

New positions in Research, Strategy and the AMR Benchmark research programme
Interested in working toward the next Access to Medicine Index, AMR Benchmark or joining the Foundation’s Strategy team?


Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine

Tomorrow, our @damidefelice joins a panel to discuss the path to #UHC & access to afforable meds:… t.co/FJCEKCB1e6

Access to Medicine's Twitter avatar
Access to Medicine

"The industry needs to be aligned with national & international priorities," says @JayasreeKIyer at #MedsWeCanTrustt.co/K8wespt2dY

U.S. Pharmacopeia's Twitter avatar
U.S. Pharmacopeia

.@JayasreeKIyer, Executive Director at @atmindex, notes that, “the Pharmaceutical industry has a role to ensure qua… t.co/VcuINRjFwo

Retweeted by Access to Medicine
Access to Medicine's Twitter avatar
Access to Medicine

“If we are going to take #UHC seriously, we have to focus on ensuring access to high-quality meds,” @JayasreeKIyert.co/Vfj6rFADIF

Access to Medicine's Twitter avatar
Access to Medicine

Today, Geneva: Our @JayasreeKIyer talks about #UHC & access to safe, high-quality medicines at #MedsWeCanTrust co-h… t.co/8m5mnB3Cnu

Encourage pharma companies Access to Medicine


Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.


Embedding pro-access governance


Mainstreaming inclusive business models


Improving industry responsiveness to public health priorities


Employing ‘access-thinking’ in product deployment


Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.